Table 2 Pharmacokinetic parameters according to metabolizer phenotype.

From: Pharmacogenetics of amfepramone in healthy Mexican subjects reveals potential markers for tailoring pharmacotherapy of obesity: results of a randomised trial

Pharmacokinetic parameters

Metabolizer phenotypes for all subjects

Slow

Intermediate

Normal

Fast

N

7

9

12

8

Cmax (ng/mL)

11.07 ± 3.49a

7.21 ± 0.91a

6.51 ± 1.16a

4.12 ± 0.89a

AUC0-t (ng/mL/h)

45.84 ± 14.69b

34.98 ± 2.13b

26.44 ± 2.87b

15.30 ± 3.74b

AUC0-∞ (ng/mL/h)

51.61 ± 15.59c

43.17 ± 10.58c

32.87 ± 2.96c

21.62 ± 4.67c

Ke

0.2013 ± 0.0431

0.2063 ± 0.0708

0.1794 ± 0.0452

0.1880 ± 0.0577

T1/2 (h)

3.58 ± 0.80

4.01 ± 1.15

4.11 ± 1.15

3.96 ± 1.08

Cl (L/h/kg)

1.53 ± 0.32d

1.80 ± 0.31d

2.30 ± 0.20d

3.64 ± 0.91d

Vd (L/kg)

7.89 ± 2.13e

9.59 ± 2.87e

13.68 ± 4.08e

19.90 ± 3.75e

  1. Data shown as mean ± standard deviation. aP ≤ 9.37 × 10−3; bP ≤ 0.001; cP ≤ 0.023; dP ≤ 0.026; eP ≤ 0.002; cP ≤ 9.79 × 10−6. Cmax, maximum plasma concentration; AUC, area under the plasma concentration-time curve; AUC0-t, AUC from time 0 to the time of last measurement; AUC0-∞, AUC from time 0 extrapolated to infinity; Ke, elimination rate constant in the terminal drug phase; T1/2, half-life drug; Vd, volume of distribution; Cl, total drug clearance.